Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Myeloma XIV: A Phase III Trial to Compare Standard and Frailty-adjusted Induction Therapy With Ixazomib, Lenalidomide and Dexamethasone (IRD) and Maintenance Lenalidomide (R) to Lenalidomide Plus Ixazomib (R+I)

NCT03720041 is registered in ClinicalTrials.gov with University of Leeds as lead sponsor.

NCT NCT03720041
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03720041 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Myeloma XIV: A Phase III Trial to Compare Standard and Frailty-adjusted Induction Therapy With Ixazomib, Lenalidomide and Dexamethasone (IRD) and Maintenance Lenalidomide (R) to Lenalidomide Plus Ixazomib (R+I)
Lead sponsor
University of Leeds
Phase
Phase 3
Overall status
Unknown status
Start date
August 4, 2020
Completion date
December 31, 2024
Enrollment
740 (estimated)
Sites
110

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma